ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection

ICoN-1 is a research study that evaluates the efficacy and safety of Clofazimine Inhalation Suspension on top of guideline-based therapy (GBT). The study is for adults with Nontuberculous Mycobacteria (NTM) lung disease caused by a bacteria known as mycobacterium avium complex (MAC). Potential participants must be ages 18-85, have the ability to inhale with a nebulizer, be able to produce sputum, have MAC-positive culture results, and be currently receiving a multi-drug regimen of guideline-based therapy for at least 6 months prior to consenting in this study.